9 results about "Leukemia Stem Cell" patented technology

The invention discloses an antibody combination and a system for detecting leukemia stem cells. The antibody combination comprises a CD7 antibody, a CD371 antibody, a CD34 antibody, a CD45RA antibody, a CD123 antibody, a CD133 antibody, a CD38 antibody, a CD45 antibody, a CD90 antibody, a CD33 antibody and a CD19 antibody. The antibody combination provided by the invention can accurately identify target cells and distinguish normal HSCs and pluripotent progenitor cells in a CD34 + CD38-cell population, and the specific antibody has abnormal expression or expression intensity change, so that leukemia stem cells can be rapidly, simply and conveniently detected with high accuracy, high sensitivity and high specificity, the sensitivity of MRD evaluation is favorably improved, and the kit has a good application prospect. Therefore, signs of disease recurrence can be found earlier, more information about disease prognosis can be provided, and doctors and patients can be helped to better understand disease prognosis and possible results.

The invention develops a double-line sequential targeted nano-drug delivery system, epigenetic regulation and traditional chemotherapy are combined, and the system is used for accurately and effectively treating acute myelogenous leukemia. The METTL3 inhibitor and the ROS-responsive daunorubicin prodrug are co-delivered in a single nano-drug, and the nano-preparation can realize continuous and double-path drug release according to the oxidation-reduction state in AML cells. In leukemia stem cells with low ROS level, STM2457 is released preferentially to induce differentiation and improve the ROS level of mitochondria, so that DA-ROS is activated, and the effect of delaying cytotoxicity is achieved. On the contrary, the AML mother cells with high ROS level can immediately trigger DA-ROS activation and release the two drugs at the same time, so that the tumor cells are directly killed. This ROS adaptive delivery strategy ensures spatial and temporal accuracy of drug release in heterogeneous AML cell populations.

The present application relates to the field of leukemia diagnosis or prognosis evaluation, in particular to a kind of acute myeloid leukemia stem cell molecular marker S1PR1, it can be applied to the diagnosis and treatment of related diseases, and further relates to related diagnostic kit and treatment product.

The invention provides application of small molecules ZQ-1-21 and derivatives thereof in prevention and treatment of leukemia brain metastasis. The invention finds that the small molecular compound ZQ-1-21 and the derivative thereof have a remarkable killing effect on various leukemia cell lines, especially drug-resistant leukemia cell lines, also have the capability of killing leukemia stem cells, and have a killing effect on human leukemia cell lines and primary leukemia cells of patients; and xenograft model leukemia derived from a patient can be treated. Furthermore, the ZQ-1-21 and the derivative thereof can effectively relieve leukemia cell infiltration of the brain of a leukemia brain metastasis model mouse, generate a treatment effect on leukemia brain metastasis or central nervous system leukemia, and have a good application prospect. In addition, it is found that ZQ-1-21 is a safe small molecule compound, and the cell viability and the clone forming ability of normal hematopoietic stem progenitor cells of people are not affected under the treatment dosage.

The present disclosure provides methods of treating acute myeloid leukemia (AML) and determining responsiveness to an AML treatment regimen, which methods involve identifying the presence or absence of myeloid / lymphocytic leukemia stem cells (M / L LSCs) in a sample from a subject.

The invention provides a correlation analysis method of leukemia stem cell transplantation prognosis influence factors. The correlation analysis method comprises the following steps: acquiring medical examination indexes of a leukemia stem cell transplantation patient; training an abnormal data identification model by using the medical examination indexes; performing data cleaning on the target medical examination index by using the abnormal data identification model to obtain a medical examination index after data cleaning; calculating the correlation between the medical examination index after each data is cleaned and the recovery index of the corresponding leukemia stem cell transplanted patient; and extracting the medical examination indexes of which the correlation is greater than a preset threshold value. By training the abnormal data recognition model, inaccurate medical examination indexes can be effectively eliminated or corrected, then correlation calculation of the medical examination indexes and patient healing indexes is completed, the remarkable influence of the medical examination indexes on patient prognosis can be deeply known, and data support is provided for formulating personalized treatment schemes.

The application belongs to the technical field of biological medicine, and particularly relates to application of a flavone small molecule compound in preparation of a drug for regulating WDR1 and / or treating leukemia. The flavone small molecule compound comprises Gambogic amide, Morellic acid, Flavopiridol hydrochloride, Gambogic Acid and / or Methylophiopogonanone B. The application research finds that the flavone small molecule compound such as Gambogic amide can effectively inhibit the activity of acute myeloid leukemia stem cells, and does not damage normal hematopoietic stem cells. The flavone small molecule compound is combined with WDR1 protein specifically expressed in the leukemia stem cells, induces cytoskeleton depolymerization, and further promotes the occurrence of leukemia stem cell apoptosis. The application provides a new direction for prevention and treatment of AML.

The application belongs to the technical field of biological medicine, and particularly relates to application of PADI2 inhibitor combined with BCL-2 inhibitor in treatment of acute myeloid leukemia. The application proves for the first time that PADI2 presents high expression in acute myeloid leukemia and is significantly related to poor prognosis of patients. Functional research shows that PADI2 is necessary for occurrence of acute myeloid leukemia and maintenance of leukemia stem cells, but is not necessary for normal hematopoietic process. In a treatment strategy, PADI2 inhibitor combined with BCL-2 inhibitor venetoclax shows a significant synergistic anti-leukemia effect and can effectively inhibit AML progression. The research not only establishes PADI2 as a potential target for treatment of acute myeloid leukemia, but also provides a theoretical basis for combined use of PADI2 inhibitor and BCL-2 inhibitor venetoclax, opens a new direction for improving the efficacy of acute myeloid leukemia, and therefore has important clinical significance and social value.

The invention relates to a method for targeted delivery of miR-21 molecules to CD34 + CD38-LSCs by using exosomes derived from leukemia stem cells (LSCs) to enhance the dryness of the leukemia stem cells and significantly enhance the proliferation capacity and multidirectional differentiation potential of the LSCs in in-vivo and in-vitro dual models. The technology provides an innovative solution for functional regulation and control, in vitro amplification and regenerative medicine application of leukemia stem cells.